DaVita CFO says DefenCath Medicare add-on payment to drop significantly in 2027

DaVita CFO Joel Ackerman said on the company's Q3 earnings call that the Medicare add-on payment for CorMedix's DefenCath, recalculated quarterly post-TDAPA, is expected to drop significantly from Q1 2027 to Q2, and to remain low or keep declining through the rest of 2027. CorMedix shares declined following the commentary.

Detected & updated continuously · Source: Nebula